These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23428308)

  • 1. High incidence of intermittent care in HIV-1-infected patients in Curaçao before and after starting cART.
    Hermanides HS; Holman R; Gras L; Winkel CN; Gerstenbluth I; de Wolf F; Duits AJ
    AIDS Care; 2013; 25(11):1411-7. PubMed ID: 23428308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss to follow-up and mortality rates in HIV-1-infected patients in Curaçao before and after the start of combination antiretroviral therapy.
    Hermanides H; Holman R; Gras L; Winkel C; Gerstenbluth I; de Wolf F; Duits A
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1300-5. PubMed ID: 23927464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of combination antiretroviral therapy in HIV type 1-infected patients treated in Curaçao compared with Antillean, Surinam, and Dutch HIV type 1-infected patients treated in The Netherlands.
    Hermanides HS; Gras L; Winkel CN; Gerstenbluth I; van Sighem A; de Wolf F; Duits AJ
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):605-12. PubMed ID: 21155654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss to follow-up in a cohort of HIV-infected patients in a regional referral outpatient clinic in Brazil.
    de Almeida MC; de Jesus Pedroso N; do Socorro Lina van Keulen M; Jácome GP; Fernandes GC; Yokoo EM; Tuboi SH
    AIDS Behav; 2014 Dec; 18(12):2387-96. PubMed ID: 24917082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients.
    Kowalska JD; Kubicka J; Siwak E; Pulik P; Firląg-Burkacka E; Horban A;
    AIDS Res Ther; 2016; 13():2. PubMed ID: 26744599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection.
    Kowalska JD; Mocroft A; Blaxhult A; Colebunders R; van Lunzen J; Podlekareva D; Hansen AB; Machala L; Yust I; Benfield T;
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1183-8. PubMed ID: 17961102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users.
    Spillane H; Nicholas S; Tang Z; Szumilin E; Balkan S; Pujades-Rodriguez M
    Trop Med Int Health; 2012 Oct; 17(10):1255-63. PubMed ID: 22863110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?
    Ateba Ndongo F; Warszawski J; Texier G; Penda I; Tetang Ndiang S; Ndongo JA; Guemkam G; Sofeu CL; Kfutwah A; Faye A; Msellati P; Tejiokem MC;
    BMC Pediatr; 2015 Sep; 15():132. PubMed ID: 26391474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
    Samji H; Taha TE; Moore D; Burchell AN; Cescon A; Cooper C; Raboud JM; Klein MB; Loutfy MR; Machouf N; Tsoukas CM; Montaner JS; Hogg RS;
    HIV Med; 2015 Feb; 16(2):76-87. PubMed ID: 25174373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.